Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Alzheimer Disease and Associated Disorders

• Publication date

  2008-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/WAD.0b013e31816653bcPMID 18580597PMCID PMC2718545
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Meta‐analysis of six‐month memantine trials in Alzheimer's disease

  2007cited by this paper
• Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials

  2007cited by this paper
• Efficacy and safety of donepezil over 3 years: an open‐label, multicentre study in patients with Alzheimer's disease

  2007cited by this paper
• Naturalistic Treatment of Alzheimer’s Disease with Galantamine

  2007cited by this paper
• Naturalistic treatment of Alzheimer's disease with galantamine: 12-month follow-up from the NATURE study.

  2007cited by this paper
• Long‐term cognitive benefits of donepezil in Alzheimer’s disease: A retrospective comparison between 1994–1999 and 2000–2004

  2007cited by this paper
• 607: Naturalistic treatment of Alzheimer’s disease with galantamine: 12-month follow-up from the NATURE study

  2007cited by this paper
• Functional Outcomes of Drug Treatment in Alzheimer’s Disease

  2007cited by this paper
• A Naturalistic Study of Galantamine for Alzheimer’s Disease

  2006cited by this paper
• A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.

  2006cited by this paper
• Challenges to demonstrating disease‐modifying effects in Alzheimer's disease clinical trials

  2006cited by this paper
• Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

  2006cited by this paper
• Effects of Cholinesterase Inhibitors on Behavioural Disturbances in Alzheimer’s Disease

  2006cited by this paper
• Memantine for dementia.

  2006cited by this paper
• Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease

  2006cited by this paper
• Commentary on “Challenges to demonstrating disease‐modifying effects in Alzheimer's disease clinical trials”

  2006cited by this paper
• Cholinesterase inhibitors for Alzheimer's disease.

  2006cited by this paper
• Do cholinergic therapies have disease‐modifying effects in Alzheimer's disease?

  2006cited by this paper
• Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying

  2006cited by this paper
• A simple and valid tool distinguished efficacy from effectiveness studies.

  2006cited by this paper
• Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

  2005cited by this paper
• Memantine for dementia.

  2005cited by this paper
• Results of a multi-level therapeutic approach for Alzheimer’s disease subjects in the “real world” (CRONOS project): a 36-week follow-up study

  2005cited by this paper
• Vitamin E and donepezil for the treatment of mild cognitive impairment.

  2005cited by this paper
• Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?

  2005cited by this paper
• External validity of randomised controlled trials: "to whom do the results of this trial apply?".

  2005cited by this paper
• Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

  2004influential reference
• Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

  2004cited by this paper
• Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease

  2004cited by this paper
• An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting

  2004cited by this paper
• Alzheimer's disease.

  2004cited by this paper
• Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.

  2004cited by this paper
• Analysis of Longitudinal Data (2nd ed.) (Book)

  2004cited by this paper
• Noninvasive Electrocardiology Has Come of Age

  2004cited by this paper
• Memantine in moderate-to-severe Alzheimer's disease.

  2003cited by this paper
• Bmc Medical Research Methodology Open Access Pragmatic Controlled Clinical Trials in Primary Care: the Struggle between External and Internal Validity

  2003cited by this paper
• The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

  2003influential reference
• Alzheimer disease in the US population: prevalence estimates using the 2000 census.

  2003influential reference
• Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.

  2003cited by this paper
• Memantine in moderate-to-severe Alzheimer's disease.

  2003cited by this paper
• Generalized Estimating Equations

  2003cited by this paper
• Analysis of Longitudinal Data

  2003cited by this paper
• Akaike's Information Criterion in Generalized Estimating Equations

  2001cited by this paper
• A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease

  2001cited by this paper
• Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial

  2000cited by this paper
• A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

  2000cited by this paper
• A 5-month, randomized, placebo-controlled trial of galantamine in AD

  2000cited by this paper
• Donepezil therapy in clinical practice: a randomized crossover study.

  2000cited by this paper
• Galantamine in AD

  2000cited by this paper
• The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1

  1999cited by this paper
• A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

  1998cited by this paper
• Cognitive test performance in detecting, staging, and tracking Alzheimer's disease.

  1995cited by this paper
• A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

  1994cited by this paper
• Cholinesterase Inhibitors in Alzheimer's Disease

  1994cited by this paper
• Deterioration on the Blessed test in Alzheimer's disease: longitudinal data and their implications for clinical trials and identification of subtypes.

  1992cited by this paper
• Treatment for Alzheimer's disease?

  1992cited by this paper
• The record of independent living

  1986cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects

  1968cited by this paper

• Novel Repurposing of Empagliflozin-Loaded Buccal Composite (Chitosan/Silk Fibroin/Poly(lactic acid)) Nanofibers for Alzheimer’s Disease Management via Modulation of Aβ–AGER–p-tau Pathway

  2026cites this paper
• Advances in gut microbiota functions in inflammatory bowel disease: Dysbiosis, management, cytotoxicity assessment, and therapeutic perspectives

  2025cites this paper
• Avenanthramide-C as Alzheimer’s Disease-Modifying Therapy: Early and Sustained Intervention Prevents Disease Progression in Mouse Models

  2025cites this paper
• Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective.

  2024cites this paper
• Mechanistic insights and emerging therapeutic stratagems for Alzheimer's disease.

  2024cites this paper
• Multifunctional nanoparticle-mediated combining therapy for human diseases

  2024cites this paper
• Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias

  2024cites this paper
• Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management.

  2024cites this paper
• Alzheimer’s disease and its treatment–yesterday, today, and tomorrow

  2024cites this paper
• Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia

  2024cites this paper
• Changes in Antidementia Medications upon Admission to the Nursing Home: Who Decides and Why? Results From a National Survey of Nursing Home Administrators.

  2023cites this paper
• Using Artificial Intelligence to Learn Optimal Regimen Plan for Alzheimer’s Disease

  2023cites this paper
• Efficacy and acceptability of anti-inflammatory eicosapentaenoic acid for cognitive function in Alzheimer's dementia: a network meta-analysis of randomized, placebo-controlled trials with omega-3 fatty acids and FDA-approved pharmacotherapy.

  2023cites this paper
• Using artificial intelligence to learn optimal regimen plan for Alzheimer’s disease

  2023cites this paper
• Antidementia Medication Use in Nursing Home Residents

  2023cites this paper
• Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases.

  2022cites this paper
• [Capabilities of combined therapy of Alzheimer's disease].

  2022cites this paper
• Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study

  2022cites this paper
• The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia

  2022cites this paper
• Aducanumab: A new hope in Alzheimer's Disease

  2022cites this paper
• Clinical efficacy of acupuncture combined with Western medicine in the treatment of mild to moderate Alzheimer disease: A protocol of a randomized controlled trial

  2022cites this paper
• Combination therapy for the treatment of alzheimer's disease: recent progress and future prospects.

  2022cites this paper
• Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects

  2022cites this paper
• Neuroprotective Effect of HIIT against GFAP Hypertrophy through Mitochondrial Dynamics in APP/PS1 Mice

  2022cites this paper
• Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

  2022cites this paper
• Anti-neurodegenerative benefits of acetylcholinesterase inhibitors in Alzheimer's disease: Nexus of cholinergic and nerve growth factor dysfunction.

  2021cites this paper
• Curcumin

  2021cites this paper
• A Retrospective Study on the Benefits of Combined Citicoline, Memantine, and Acetylcholinesterase Inhibitor Treatments in Older Patients Affected with Alzheimer’s Disease

  2021cites this paper
• Combination Drug Therapy for the Management of Alzheimer’s Disease

  2020cites this paper
• Challenges of Combination Therapies in Alzheimer’s Disease

  2020cites this paper
• Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer’s Disease: Are Irreversible Inhibitors the Future?

  2020cites this paper
• [Alzheimer disease].

  2020cites this paper
• Electroacupuncture improves cognitive deficits and insulin resistance in an OLETF rat model of Al/D-gal induced aging model via the PI3K/Akt signaling pathway.

  2020cites this paper
• Деменции позднего возраста: факторы, ассоциированные со скоростью прогрессирования деменции. Часть 2

  2020cites this paper
• Acupuncture for the Treatment of Alzheimer's Disease: An Overview of Systematic Reviews

  2020cites this paper
• Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders

  2019cites this paper
• Chapter 1 Alzheimer ’ s Disease : A Clinical Perspective

  2019cites this paper
• Memantine for dementia.

  2019cites this paper
• Combination of drug and stem cells neurotherapy: Potential interventions in neurotrauma and traumatic brain injury

  2019cites this paper
• Present Algorithms and Future Treatments for Alzheimer’s Disease

  2019cites this paper
• The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management.

  2019cites this paper
• Current and Future Treatments in Alzheimer's Disease

  2019cites this paper
• Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies.

  2019cites this paper
• Spezielle Aspekte bezogen auf Organsysteme nach geriatrisch-klinischer Bedeutung

  2019cites this paper
• 알츠하이머 치매 약물치료의 현황과 미래

  2018cites this paper
• Clinical Psychopharmacology for Neurologists

  2018cites this paper
• Past and Future of Drug Treatments for Alzheimer's Disease

  2018cites this paper
• Stem cells and combination therapy for the treatment of traumatic brain injury

  2018cites this paper
• An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease

  2018cites this paper
• Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity

  2018cites this paper
• The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

  2018cites this paper
• Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer’s disease

  2018cites this paper
• Traumatic brain injury as a risk factor for dementia: Literature Review

  2018cites this paper
• Design And Assessment of Small Molecules as Free Radical Scavengers and Potential Multi-Target Therapeutic Agents against Alzheimer’s Disease, Diabetes and Cancer

  2018cites this paper
• Pathogenic Feed-Forward Mechanisms in Alzheimer’s and Parkinson’s Disease Converge on GSK-3

  2018cites this paper
• Effects of Choline Alfoscerate and Memantine on Memory Improvement of Scopolamine-induced Memory Impairment animal Model of Alzheimer’s Disease

  2017cites this paper
• COMBINATION COMPRISING PARTHENOLIDE FOR USE IN THE TREATMENT OF ALZHEMERS DISEASE AND OTHER NEURODEGENERATIVE DSORDERS

  2017cites this paper
• The effect of electroacupuncture combined with donepezil on cognitive function in Alzheimer’s disease patients: study protocol for a randomized controlled trial

  2017cites this paper
• Network pharmacology-based study on the mechanism of action for herbal medicines in Alzheimer treatment.

  2017cites this paper
• DFP: Therapie der Alzheimer-Demenz: Status quo und Zukunftsperspektiven

  2017cites this paper
• Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan

  2017cites this paper
• [Memantine: from the original brand to generics].

  2017cites this paper
• Early-versus Late-Onset Alzheimer Disease: Long-Term Functional Outcomes, Nursing Home Placement, and Risk Factors for Rate of Progression

  2017cites this paper
• Analysis of Diagnostic, Preventive, and Disease-Modifying Therapeutic Measures of Alzheimer’s Disease

  2017cites this paper
• Pharmacist’s role in pharmacotherapeutic management of Alzheimer’s disease

  2017cites this paper
• Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial

  2017cites this paper
• Coriandrum sativum Suppresses Aβ42-Induced ROS Increases, Glial Cell Proliferation, and ERK Activation.

  2016cites this paper
• Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine

  2016cites this paper
• A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease

  2016cites this paper
• Complex Treatment of the Patients with Alzheimer?s Disease Using Stem Cell Preparations Including Extracted Fetal Stem Cells

  2016cites this paper
• Cholinesterase Inhibitor Therapy in Alzheimer’s Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates

  2016cites this paper
• Chapter 17 – Memantine (Generic and Namenda XR)

  2016cites this paper
• Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease

  2016cites this paper
• The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.

  2016cites this paper
• Combined treatment with memantine/es‐citalopram for older depressed patients with cognitive impairment: a pilot study

  2016cites this paper
• Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial

  2016cites this paper
• Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease

  2016cites this paper
• Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses.

  2016cites this paper
• The role of hypertension and inflammation on the cognitive symptoms of Alzheimer's disease patients

  2016cites this paper
• Development and Validation of the

  2016cites this paper
• In the Information Age, do dementia caregivers get the information they need? Semi-structured interviews to determine informal caregivers’ education needs, barriers, and preferences

  2016cites this paper
• Medications used in dementia: a review of evidence

  2015cites this paper
• The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan

  2015cites this paper
• A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

  2015influential citation
• Benefits and risks of add-on therapies for Alzheimer's disease.

  2015cites this paper
• A Survey on Dementia Training Needs Among Staff at Community-Based Outpatient Clinics

  2015cites this paper
• Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

  2015cites this paper
• Psychopharmacologic Agents to Enhance Cognition in Alzheimer’s Disease

  2015cites this paper
• The Effectiveness and Safety of Acupuncture for Patients With Alzheimer Disease

  2015cites this paper
• Memantine ER/Donepezil: A Review in Alzheimer’s Disease

  2015cites this paper
• Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use

  2015cites this paper
• Slowing the progression of Alzheimer's disease; what works?

  2015cites this paper
• The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease

  2015cites this paper
• Alzheimer’s Disease: A Look at Current and Future Treatment Options

  2015influential citation
• Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study

  2015cites this paper
• Memantine Extended Release (28 mg Once Daily): A Review of Its Use in Alzheimer’s Disease

  2015cites this paper
• EFNS‐ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

  2015cites this paper
• The Combination of Aricept with a Traditional Chinese Medicine Formula, Smart Soup, May Be a Novel Way to Treat Alzheimer's Disease

  2015cites this paper
• Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis

  2015influential citation
• Ведение пациентов с дисциркуляторной энцефалопатией в амбулаторной практике

  2015cites this paper